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Abstract 
In earlier studies we showed that the expression patterns of platelet-derived growth factor (PDGF) a- and /3-receptors differ between 
normal and malignant mesothelial cell lines. Normal mesothelial cells predominantly express PDGF a-receptor mRNA and protein, 
whereas most malignant mesothelioma cell lines produce PDGF/3-receptor mRNA and protein. In this paper we studied regulation of this 
differential PDGF receptor mRNA expression. Such an analysis is of importance in view of the suggested PDGF autocrine activity 
involving the PDGF/3-receptor in mesothelioma cells. The results obtained in this study demonstrate hat malignant mesothelioma cell 
lines are not only capable of PDGF fl-receptor t anscription but of a-receptor t anscription as well, as evidenced from run off analysis and 
RT-PCR using a-receptor specific primers. However, the fact that PDGF a-receptor mRNA could not be detected by Northern blot 
analysis, even after cycloheximide treatment, suggests a difference in steady-state PDGF a-receptor mRNA expression levels between 
normal and malignant mesothelial cell lines, which is likely to be caused by a post-transcriptional mechanism. In normal mesothelial cells 
a half-life of more than 6 h was observed for PDGF a-receptor mRNA. In the majority of malignant mesothelioma cell lines clear PDGF 
/3-receptor mRNA expression was seen. The half-life of the PDGF fl-receptor t anscript was at least 6 h in these cells. In contrast, hardly 
any PDGF/3-receptor transcription was observed in run off assays in normal mesothelial cells, suggesting that differences in fl-receptor 
transcriptional initiation most probably account for the inability to clearly detect PDGF fl-receptor t anscripts in these cells. Transforming 
growth factor/3-1 (TGF-/31), which is being produced in active form by mesothelial cells was evaluated for its potential role in regulation 
of the differential PDGF receptor expression in these cells. Stimulation with TGF-fl 1 revealed ecreased PDGF a-receptor mRNA 
expression in normal mesothelial cells. The effect on PDGF 0-receptor mRNA in the malignant mesothelioma cell lines was variable. 
Although the TGF-fl I effect cannot entirely explain the differential PDGF receptor expression pattern, TGF-/31 may nevertheless play a 
role in downregulation f an (already) low PDGF a-receptor mRNA level in malignant mesothelioma cell lines. 
Keywords: Platelet-derived growth factor or-receptor; Platelet-derived growth factor/3-receptor; Human mesothelial cell line; Malignant mesothelioma 
1. Introduction 
Platelet-derived growth factor (PDGF) is a mitogenic 
factor for cells of mesenchymal origin [15]. It is composed 
of two disulfide-bonded polypeptides, that are encoded by 
Abbreviations: PDGF, platelet-derived growth factor; TGF-/3, trans- 
forming growth factor-fl; EGF, epidermal growth factor; HC, hydrocorti- 
sone; FCS, fetal calf serum; CHX, eyclobeximide; Act D, actinomycin D; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse 
transcription polymerase chain reaction. 
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the distinct, but structurally related, PDGF A-chain and 
B-chain genes [6]. Homodimeric (AA and BB) as well as 
heterodimeric (AB) forms of PDGF have been observed. 
In addition, two homologous PDGF receptor subtypes have 
been described, the PDGF o~-receptor and PDGF/3-recep- 
tor [14]. These two receptors how different affinities for 
the various dimeric PDGF forms. PDGF c~-receptors bind 
all PDGF isoforms (AA, AB, and BB) with high affinity, 
whereas PDGF/3-receptors only show high affinity bind- 
ing of PDGF-BB [26]. Ligand binding results in receptor 
dimerization and subsequent activation through cross-phos- 
phorylation on tyrosine residues [18]. 
PDGF and PDGF receptors, expressed by various cell 
types like platelets, macrophages and cytotrophoblasts (for 
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a review, see [25]) play a role in, e.g., wound healing and 
developmental processes. Furthermore, PDGF has been 
suggested to play a role in several tumour types as well 
(for a review, see [24,36]). Evidence for autocrine activity 
of PDGF has been presented in glioblastoma and astrocy- 
toma cell lines [27,30]. In view of the involvement of 
PDGF and PDGF receptors in several physiological and 
pathophysiological processes, transcriptional regulation of 
PDGF chains and receptors i  an important topic to study. 
Transcriptional regulation constitutes the first regulatory 
level of the biological action of PDGF as it determines the 
availability of ligands and signal-transducing receptors. 
Although studies on regulatory elements involved in tran- 
scription of the PDGF A-chain and B-chain genes have 
been performed in many cell types (for a recent review, 
see [17]), similar reports on PDGF receptor elements have 
been limited so far. Recently, studies on the promoter and 
upstream regulatory elements of the murine PDGF a-re- 
ceptor [35] and PDGF/3-receptor [3] and the human PDGF 
a-receptor [1] have been published. 
Human malignant mesothelioma is a tumour of meso- 
dermally derived tissues that is predominantly observed in 
the pleura. Based on in vitro and in vivo expression data, 
PDGF was suggested to play a role in the tumorigenesis of
malignant mesothelioma [20,31,33]. In summary, malig- 
nant mesothelioma cells were found to express PDGF 
A-chain and B-chain mRNA at high levels, whereas nor- 
mal mesothelial cells only expressed low levels of PDGF 
A-chain mRNA. Furthermore, xpression of PDGF a-re- 
ceptor mRNA and protein was demonstrated in non-malig- 
nant mesothelial cells, whereas PDGF /3-receptor tran- 
scripts and proteins were observed in the majority of 
malignant mesothelioma cells. Membrane-bound PDGF 
a-receptor proteins were also found to be expressed by the 
latter [20]. In our normal and malignant mesothelial cell 
lines we previously analyzed regulation of PDGF A-chain 
and B-chain transcription ([19] and unpublished work). We 
now report on the regulation of the differential PDGF 
receptor mRNA expression in normal and malignant 
mesothelial cell lines, as insight into regulation of PDGF 
receptors in mesothelioma cells is relevant in view of the 
possible PDGF-driven autocrine loop in these cells. Direct 
evidence for such an autocrine loop should be obtained in 
future studies by introduction of, e.g., dominant-negative 
receptors [29] or dominant-negative ligands [27,30]. It has 
been shown in several studies that mRNA expression of 
PDGF chains and PDGF receptors is regulated by, e.g., 
acidic fibroblast growth factor and interleukin-1 [23,37,38]. 
Transforming rowth factor-/3 (TGF-/3) is probably one of 
the most extensively studied regulators of PDGF receptor 
expression. TGF-/3 stimulation has been shown to result in 
downregulation of PDGF a-receptor mRNA in, e.g., fi- 
broblasts and smooth muscle cells [4,22], whereas upregu- 
lation of PDGF /3-receptor messenger levels was seen in 
smooth muscle and mesangial cells [13,16]. As active 
TGF-/3 has been shown to be endogenously produced by 
mesothelial and mesothelioma cells [10,12,21], we evalu- 
ated whether TGF-/3 may contribute to the differential 
expression of PDGF a- and /3-receptors in mesothelial cell 
lines. 
Collectively, the results show that PDGF a- and /3-re- 
ceptor expression are differentially regulated between or- 
mal and malignant mesothelial cells. The mechanisms that 
most probably account for this differential PDGF receptor 
expression are discussed. The obtained results indicate that 
the mesothelial cell lines may constitute an useful model 
system for future studies on regulation of PDGF receptor 
expression and on the regulatory elements involved. 
2. Materials and methods 
2.1. Cell lines and growth conditions 
Experiments were performed using the human malig- 
nant mesothelioma cell lines Mero- 14, Mero-25, Mero-41, 
Mero-48c, Mero-72, Mero-82, Mero-84, and Mero-95 and 
the normal human mesothelial cell lines NM-9, NM-12, 
NM-21, NM-23, and NM-25 [20,32]. The cell lines were 
routinely cultured in Ham's F10 medium (Gibco, Paisley, 
UK) with 15% fetal calf serum [32]. Epidermal growth 
factor (EGF; Collaborative Research, Lexington, MA, 
USA; 10 ng/ml) and hydrocortisone (HC; 0.4 /zg/ml) 
were added to the culture medium of normal mesothelial 
cells. In some experiments cells were exposed to cyclohex- 
imide (CHX; Sigma, St. Louis, MO, USA) at a concentra- 
tion of 10 /zg/ml medium for 2 h or to actinomycin D
(Act D; Merck Sharp & Dohme, Rahway, NJ, USA) at a 
concentration f 5 ~g/ml  medium for 1-6 h. 
Prior to TGF-/31 treatment, cells were cultured under 
serumfree conditions in Ham's F10 medium (+EGF/HC 
for normal cells) supplemented with 0.1 mg/ml BSA 
(Sigma), 10 /zg/ml human transferrin (Behringwerke, 
Marburg, Germany), 10 /~g/ml insulin (Sigma), and 50 
nM sodium selenite (Merck, Darmstadt, Germany) for 24 
h. Subsequent s imulation with human TGF-/31 (2 ng/ml; 
24 h; R&D, Abingdon, UK) was performed in this 
serum-free medium as well. 
2.2. Probes 
For hybridization of Northern blots the 1.5 kb EcoRI 
(extracellular) PDGF a-receptor [8], the 1.7 kb EcoRI- 
HindlII (extracellular) PDGF/3-receptor [7], and the 0.7 kb 
EcoRI-PstI GAPDH [5] cDNA fragments were used as 
probes. For nuclear un off analysis the same extracellular 
PDGF a-receptor and r-receptor f agments [7,8] as well as 
the 1.25 kb PstI fl-actin fragment from pAct [9] were all 
subcloned in the multicloning site of pUC and subse- 
quently spotted onto nitrocellulose filters prior to hy- 
bridization. 
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2.3. Northern and Southern blot analyses 
RNA isolation, Northern blotting and subsequent hy- 
bridization were performed as described elsewhere [19]. 
Isolation of chromosomal DNA and transfer to Hybond-N 
(Amersham, UK) membranes were performed according to 
standard procedures. Hybridization and autoradiography 
were described previously [31]. 
2.4. Nuclear run off assay 
Isolation of nuclei, in vitro labeling of nuclear RNA and 
hybridization were described elsewhere [19]. 
The PDGF a-receptor cDNA clone pSV7dl5EB and a 
full-length PDGF /3-receptor cDNA clone were used as 
positive and negative controls, respectively [7,8]. No am- 
plified products were seen using these primers on chromo- 
somal DNA and non-reverse transcribed RNA. All samples 
were checked for the amount of analyzable cDNA using 
specific HPRT gene primers (forty cycles of 30 s at 94°C, 
30 s at 55°C, and 1 min at 72°C). Ethidium bromide 
analysis and hybridization of filters with amplified PCR 
products were performed as described previously [19]. 
PDGF a-receptor-specific oligo aR-3A (5'-TCACTGA- 
GATCACCACTGATGTGG-3'; bp 1207-1230) was used 
as probe for hybridization. 
2.5. RT-PCR analysis 
For reverse transcription (RT) 1 /zg total RNA was 
denatured at 65°C for 10 min and mixed with 10 /zg/ml 
oligo(dT)15 (Pharmacia, Uppsala, Sweden), 2.5 A260/ml 
(dN) 6 (Pharmacia), avian myoblastoma virus (AMV) RT 
buffer (50 mM Tris-HC1, pH 8.3; 50 mM KC1; 10 mM 
MgCI2; 1 mM dithiothreitol; 1 mM EDTA; 10 /zg/ml 
bovine serum albumin), 1 mM dNTPs, 1 mM spermidine- 
HC1 (Sigma), 40 U RNAsin (Promega, Madison, WI, 
USA), and 5 U AMV RTase (Promega) and incubated for 
55 min at 39°C. For amplification of PDGF a-receptor 
sequences cDNA was mixed with Taq buffer (10 mM 
Tris-HC1, pH 8.3; 50 mM KC1; 1.5 mM MgCI2; 0.01% 
(m/v) gelatin), 0.2 mM dNTPs, 20 pmol sense primer 
aR-7 (5'-CTGGAAGAAATCAAAGTCCCATCC-3'; bp 
909-932 in the extracellular domain, according to the 
sequence in [8]), 20 pmol antisense primer aR-8 (5'- 
TGAGCCATGGTGATCATCGACC-3'; bp 1388-1409 in 
the extracellular domain), and 1 U Taq polymera~c (Per- 
kin-Elmer Cetus, Norwalk, CT, USA). Forty cycles of 30 s 
at 94°C, 30 s at 65°C, and 30 s at 72°C were performed. 
3. Results 
3.1. Differential regulation of PDGF a- and B-receptor 
mRNA expression in mesothelial cell lines 
As normal and malignant mesothelial cell lines display 
a differential PDGF receptor mRNA expression pattern 
and as there are no indications for consistent cytogenetic 
and/or genomic aberrations, run off assays were per- 
formed to study the nuclear PDGF a- and fl-receptor 
mRNA levels in these cell lines. Nuclear PDGF a-receptor 
RNA could be demonstrated in both normal and malignant 
mesothelial cell lines (Table 1). In Fig. 1 this is shown for 
NM-9 and Mero-14 as representative examples. Nuclear 
PDGF B-receptor transcripts were only detectable in the 
malignant mesothelioma cell lines and hardly or not in the 
normal mesothelial cell lines tested (Fig. 1 and Table 1). 
All cell lines tested clearly expressed nuclear RNA of the 
constitutively transcribed /3-actin gene. 
Culturing of several normal and malignant mesothelial 
cells with the protein synthesis inhibitor cycloheximide 
Table 1 
Summary of data on PDGF a-receptor and l~-receptor mRNA detection in normal and malignant mesothelial cell lines under various experimental 
conditions 
Cell line PDGF a-receptor PDGF/3-receptor 
nuclear RNA mRNA (CHX mRNA mRNA half-life 
(run off assay) treated samples) (RT-PCR) (Act D treated 
samples) 
nuclear RNA mRNA (CHX mRNA half-life 
(run off assay) treated samples) (Act D treated 
samples) 
NM-9 + + + min, 4 -6  h - - 
NM-12 + + ND ND - - 
NM-23 ND ND + ND ND ND 
Mero-14 + - + / - no mRNA + + 
detectable 
Mero-25 + - + / - ND + / - + / - 
Mero-41 ND - + / - ND + + 
Mero-48c ND - + / - ND + + 
Mero-82 + - + / - no mR_NA + / - + / - 
detectable 









min. 4 -6  h 
ND 
ND: not determined. 
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Fig. 1. Nuclear un off analysis using 32 P-labeled nuclear RNA of normal 
mesothelial (NM-9) and malignant mesothelioma (Mero-14) cell lines. 
The nitrocellulose blots contained plasmids pUC, pUC plus actin, pUC 
plus PDGF or-receptor, and pUC plus PDGF/3-receptor. 
(CHX; 10 /xg/ml) did not significantly affect the PDGF 
r-receptor mRNA levels in both cell types (Table 1). This 
is shown for NM-12 and Mero-14 in Fig. 2. PDGF/3-re- 
ceptor mRNA expression was hardly or not detectable in 
untreated as well as CHX-treated normal mesothelial cells. 
Furthermore, CHX treatment did not alter the differential 
expression of PDGF a-receptor transcripts in normal and 
malignant mesothelial cell lines, as determined by North- 
ern blot analysis (Fig. 2 and Table 1). In CHX-treated 
malignant mesothelioma cell lines no PDGF a-receptor 
mRNA could be demonstrated. Moreover, the use of higher 
concentrations of CHX (20-30 /xg/ml) still did not result 
in detectable PDGF a-receptor expression in these cells 
(data not shown). 
3.2. Detection of PDGF a-receptor mRNA by RT-PCR 
To obtain further evidence for PDGF a-receptor gene 
expression in malignant mesothelioma cell lines, we per- 
formed RT-PCR analysis. Amplification of PDGF a-recep- 
tor cDNA clone pSV7dl5EB (used as positive control) 
with primers a R-7 and a R-8, located in the extracellular 
domain, resulted in a 501 bp band. A fragment of similar 
size could also be amplified from cDNA of normal 
mesothelial cells (Fig. 3 and Table 1). In the majority of 
our malignant mesothelioma cell lines such a 501 bp band 
could be detected as well, although the intensity was 
generally much lower than in normal mesothelial cell lines 
(Fig. 3 and Table 1). However, distinct samples of a single 
malignant mesothelioma cell line were not always positive, 
further indicating low expression levels indeed. Since the 
PDGF a- and /3-receptor sequences are quite homologous 
in many regions, cross-reactivity of the aR-7 and aR-8 
primers with r-receptor sequences in these cells had to be 
excluded. Therefore, we checked the specificity of the 
PDGF a-receptor primers in various ways. EcoRV diges- 
tion of the amplified fragments resulted in the expected 
244 and 257 bp PDGF c~-receptor-cDNA fragments (data 
not shown), whereas hybridization with the aR-3A oligo 
further confirmed the PDGF a-receptor origin of the am- 
plified cDNA fragments (Fig. 3). Furthermore, the lack of 
amplification of the PDGF /3-receptor cDNA construct 
with these primers excluded cross-reactivity with PDGF 
r-receptor sequences. Finally, genomic DNA, non-reverse 
transcribed RNA, and H20 controls were all negative. 
Despite the low expression levels, the results are thus in 
agreement with the data obtained in run off assays, indicat- 
ing that malignant mesothelioma cells are in principle 
capable of producing PDGF a-receptor mRNA as well. 
3.3. Stability of PDGF a- and [3-receptor t anscripts 
The stability of the PDGF a- and /3-receptor t anscripts 
was studied by Northern blot analysis in a few normal and 
malignant mesothelial cell lines (NM-9, Mero-14, Mero- 
82), which were treated with actinomycin D (Act D) for 
different times. The PDGF a-receptor and PDGF/3-recep- 
tor mRNA levels remained relatively stable during a 4 h 
treatment with Act D, suggesting half-lives of at least 4 h 
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Fig. 2. Northern blot analysis of total RNA from normal mesothelial 
(NM-12) and malignant mesothelioma (Mero-14) cell lines. Total RNA 
(25 /zg) of cells cultured in the absence ( - )  or presence (+)  of l0 
p.g/ml cycloheximide (CHX) was blotted and hybridized to PDGF 
or-receptor, PDGF/3-receptor, and GAPDH probes. 
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Fig. 3. Reverse-transcription PCR analysis of RNA from normal mesothelial (NM-9, NM-23) and malignant mesothelioma (Mero-41, Mero-48c, Mero-82) 
cell lines. Upper panel: ethidium bromide analysis of amplified products, using cDNA from PDGF a-receptor clone pSV7d 15EB as positive control (+). 
PDGF B-receptor cDNA was used to exclude cross-reactivity of the aR-7 and c~R-8 primers (-).  Genomic DNA and H20 were used as negative 
controls. Lower panel: after blotting the filter was hybridized to a-receptor-specific oligo oLR-3A. 
In fact both transcripts are rather stable, as even prolonged 
exposure (6 h) to Act D did not result in significant 
decreases in a-receptor levels in normal mesothelial cell 
lines or in B-receptor levels in mesothelioma cell lines 
(data not shown). Further support for the high PDGF 
receptor mRNA stability in these cells came from the 
observation that at the utilized Act D concentration the 
PDGF A-chain messenger half-life of these cells was 2 to 
3 h, which is in agreement with our earlier findings [19]. 
Unfortunately, the stability of PDGF a-receptor transcripts 
in malignant mesothelioma cell lines could not be deter- 
mined due to the inability to detect these messengers in
hrs Act.D 




0 2 3 4 
Mero- 14 
0 2 3 4 hrs Act.D 
kb PDGF 13R 
- 6 .0  
- 28S  
GAPDH GAPDH 
1.2 - - 1.2 
Fig. 4. Northern blot analysis of total RNA from normal mesothelial (NM-9) and malignant mesothelioma (Mero-14) cell lines. Total RNA (25 /xg) of 
NM-9 cells cultured in the presence of 5 ~g/ml actinomycin D (Act D) for the indicated times was blotted and hybridized to PDGF a-receptor and 
GAPDH probes. Similarly, total RNA of Mero-14 cells cultured with Act D, was hybridized toPDGF B-receptor and GAPDH probes. 
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these cell lines by Northern blot analysis. RT-PCR of Act 
D-treated cells has not been performed because the quality 
of the RNA isolated from the Act D-treated cells was not 
constant enough for reliable determination of PDGF a-re- 
ceptor mRNA half-lives in these cells. 
A NM-21 NM-25 
a b c a b 
PDGF o~R 
kb 
7 .0 -  
28S - 
GAPDH 
1.2 -  
B Mero-72 Mero-84 
a b c a b c 
PoGF 
6.0 -  
28S - 
GAPDH 
3.4. Differential effects of TGF-~I on PDGF a- and 
[3-receptor mRNA levels 
To further identify which factor(s) may be involved in 
regulation of the differential PDGF rceptor expression 
between ormal and malignant mesothelial cells, we evalu- 
ated the possible contribution of TGF-/31. TGF-fl I is one 
of the most extensively studied regulators of PDGF recep- 
tor expression and is known to be produced in an active 
form by mesothelial cells. In a pilot experiment, hat was 
designed to identify conditions for TGF-/31 stimulation, 
maximal effects were seen under serumfree conditions 
using 2 ng /ml  TGF-/31 for 24 h (data not shown). Serum- 
free culture was found to slightly alter PDGF a- and 
/3-receptor mRNA levels in normal and malignant 
mesothelial cells, respectively, but no significant induction 
of the otherwise undetectable receptor type was seen. 
Based on these results, the effect of TGF-fl 1 stimulation 
was analyzed in a panel of cell lines. Serumfree culture of 
normal mesothelial cell lines (NM-21 and NM-25) for an 
additional 24 h resulted in slightly altered PDGF a-recep- 
tor mRNA expression levels (Fig. 5A, lanes a, b). In 
parallel cultures addition of 2 ng /ml  TGF-/31 caused 
downregulation of a-receptor messenger expression in 
these cell lines, as can be seen when comparing lanes b 
and c. In malignant mesothelioma cell lines no PDGF-a 
receptor mRNA expression was seen under the conditions 
tested. The effect of serumfree culture and TGF-/31 stimu- 
lation on PDGF r-receptor mRNA levels in the malignant 
mesothelioma cell lines tested, was variable. In two out of 
six (Mero-82, Mero-84) an increase in PDGF r-receptor 
level was seen after serum depletion, which was even 
further increased by TGF-/31 stimulation (Fig. 5B, lanes b, 
c). In Mero-72 the level was slightly increased by serum 
depletion, but TGF-/31 did not have a clear additional 
effect (Fig. 5B, lanes b, c). Of the other three cell lines 
tested, one did not demonstrate PDGF r-receptor mRNA 
expression under all conditions (Mero-95), whereas the 
other two showed rather low (Mero-25, Mero-41) expres- 
sion levels that were hardly affected by serum removal or 
TGF-/31 stimulation (data not shown). In normal mesothe- 
lial cell lines a weak enhancing effect was seen after serum 
removal. 
4. D iscuss ion  
1.2-  
F ig .  5. Northern blot analysis of total RNA from normal mesothelial 
(NM-21, NM-25) (A) and malignant mesothelioma (Mero-72, Mero-84) 
(B) cell lines. Cells were either cultured without serum (lanes a), cultured 
without serum for another 24 h. (lanes b) or cultured in the presence of2 
ng/ml transforming growth factor-/31 (TGF-/31) under serumfree condi- 
tions (lanes c). Total RNA (25 /xg) was blotted and hybridized to PDGF 
or-receptor (A) and PDGF r-receptor (B) probes. GAPDH hybridization 
was done for control. 
We previously reported on PDGF a-receptor mRNA 
expression in normal mesothelial cells, whereas on North- 
ern blots only PDGF /3-receptor transcripts could be de- 
tected in nearly all malignant mesothelioma cell lines [33]. 
These differences are not likely to be caused by culturing, 
as has been described for fibroblasts and smooth muscle 
cells [28]. Addition of EGF and HC (added to normal 
mesothelial cells cultures) and serum removal just slightly 
modulated PDGF receptor mRNA levels in both normal 
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and malignant mesothelial cell lines and, most importantly, 
did not cause induction of the otherwise undetectable 
PDGF receptor subunit ([34] and this study). Moreover, the 
differential PDGF receptor expression patterns were also 
seen in uncultured normal and malignant mesothelial cells 
[20]. Cytogenetic analysis did not demonstrate any consis- 
tent chromosomal berration on chromosomes 4 (a-recep- 
tor) or 5 (/3-receptor) in the malignant mesothelioma cell 
lines [33]. Furthermore, in the present study no PDGF 
a-receptor gene rearrangements or intragenic deletions 
were detected in the malignant mesothelioma cell lines by 
Southern blot analysis using EcoRI-digested DNA (data 
not shown). We therefore valuated transcriptional nd 
post-transcriptional regulation of the differential PDGF 
receptor mRNA pattern in mesothelial cells. We conclude 
that the absence of clear PDGF/3-receptor mRNA levels in 
total RNA of normal mesothelial cell lines is probably 
caused by lack of transcription of this gene rather than by 
rapid decay of unstable messengers. In contrast, the ab- 
sence of PDGF a-receptor mRNA on Northern blots of 
malignant mesothelioma cell lines cannot be explained 
similarly. Several ines of evidence suggest hat malignant 
mesothelioma cell lines are actually capable of transcribing 
the PDGF a-receptor gene. By nuclear un off analysis as 
well as RT-PCR PDGF a-receptor transcripts could be 
detected, although in the latter assay the expression level 
was rather low and variable as compared to normal 
mesothelial cells. Prolonged exposure of blots containing 
poly(A) + RNA of malignant mesothelioma cell lines also 
showed a faint PDGF a-receptor hybridization signal (data 
not shown). Furthermore, other investigators found PDGF 
a-receptor t anscripts in their malignant mesothelioma cell 
lines using the sensitive RNase protection analysis [11]. In 
line with all these findings we also observed membrane- 
bound PDGF a-receptor proteins on malignant mesothe- 
lioma cells using immunostaining techniques [20]. Further- 
more, in view of these data the earlier observed binding of 
radiolabeled ~25I-PDGF-AA to malignant mesothelioma 
cell lines should not be interpreted as background binding, 
but rather as specific, though low, binding of PDGF-AA to 
PDGF a-receptors on these cells [33]. Despite the demon- 
stration of PDGF a-receptor expression in malignant 
mesothelioma cell lines, it remains to be determined in 
future studies whether growth stimulation via PDGF a-re- 
ceptors is really of biological importance in these cells as 
well. 
Being one of the best studied regulators of PDGF 
receptor expression and being produced in active form by 
both normal and malignant mesothelial cells, TGF-/31 was 
evaluated for its putative contribution to the differential 
PDGF receptor expression in mesothelial cell lines. After 
stimulation with TGF-/31, no induction of PDGF a- and 
/3-receptor mRNA was seen in normal and malignant 
mesothelial cells, respectively. However, PDGF a-receptor 
mRNA levels in normal mesothelial cells were found to be 
decreased by TGF-/31, which is similar to what has been 
described for, e.g., smooth muscle cells and fibroblasts 
[4,22]. The effect of TGF-/31 on PDGF/3-receptor expres- 
sion in malignant mesothelioma cell lines was variable, 
which also fits in with data from other cell types, like 
smooth muscle and mesangial cells [13,16,22]. Taken to- 
gether, the effect of TGF-/31 stimulation is not likely to 
explain the differential PDGF receptor expression. Never- 
theless, the low PDGF a-receptor mRNA expression in 
malignant mesothelioma cell lines may well be (partly) the 
consequence of a-receptor downregulation by endoge- 
nously produced TGF-/31. However, the latter suggestion 
awaits further experimental proof. Recently, it has been 
shown that antisense messengers against TGF-/32 and to a 
lesser extent against TGF-/31, resulted in growth-inhibition 
of mesothelioma cells in vitro and in reduced tumorigenic- 
ity and increased T-lymphocyte infiltration in vivo [I0]. 
Together these results uggest an important role for TGF-/3 
in mesothelial carcinogenesis. The results described in this 
study indicate that modulation of PDGF receptor mRNA 
expression may be another effect of TGF-/31 in (part of 
the) maligrznt mesothelioma cells. 
The apparent inability to detect PDGF a-receptor mes- 
sengers in malignant mesothelioma cells by Northern blot 
analysis, is most probably due to rapid degradation, sug- 
gesting that the PDGF a-receptor t anscript is rather unsta- 
ble in malignant mesothelioma cells. In contrast, the a-re- 
ceptor messenger in normal mesothelial cells is quite 
stable, with a half-life of at least 6 h. As inhibition of 
protein synthesis did not seem to influence PDGF a-recep- 
tor mRNA stability in malignant mesothelioma cells, labile 
degrading proteins are not likely to be involved. However, 
CHX-insensitive proteins may very well be responsible for 
the observed ifference in stability. Alternatively, it may 
be that the absence of certain degradation-protecting pro-
teins or the presence of mutations in 3' untranslated se- 
quences (UTS) cause differences in PDGF a-receptor mes- 
senger stability between ormal and malignant cells. AU- 
UUA regions in the 3'UTS have earlier been shown to 
play a role in stability of, e.g., GM-CSF transcripts [2]. It 
remains to be determined if any of these mechanisms 
accounts for the apparent difference in PDGF a-receptor 
stability between ormal and malignant mesothelial cells. 
Recently there has been a report in which the murine 
PDGF/3-receptor p omoter was described [3]. Concerning 
the PDGF a-receptor, a minimal promoter region of 93 bp 
relative to the transcription start was identified, that func- 
tioned in a way that mirrored mouse tissue-specific PDGF 
o~-receptor expression [35]. Moreover, a similar though 
larger promoter egion was identified in human Tera-2 
cells [l]. It would be interesting to see whether this 
promoter region would be sufficient o drive PDGF a-re- 
ceptor transcription i mesothelial cells as well. Based on 
the earlier discussed ifferences and similarities in regula- 
tion of PDGF a-receptor and /3-receptor expression, nor- 
mal and malignant mesothelial cell lines could be very 
helpful for characterization f promoter and upstream reg- 
70 A. W. Langerak et al. / Biochimica et Biophysica Acta 1305 (1996) 63-70 
ulatory elements of both PDGF receptor genes in human 
cells. 
In conclusion, data on regulation of PDGF receptor 
expression collectively suggests that both PDGF a- and 
/3-receptor transcripts can be expressed by mal ignant 
mesothel ioma cell lines. However, there seems to be a 
difference in stability between PDGF a- and /3-receptor 
transcripts. Moreover, o~-receptor processing in mal ignant 
mesothel ioma cell l ines seems to be different from that in 
normal mesothelial cell l ines as well. Further identification 
of the mechanism behind this processing will therefore be 
a topic of future studies. 
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